



UNITED STATES DEPARTMENT OF COMMERCE

Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

1645

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. 5 A-67984/RFT/ 09/500,376 02/08/00 CHANG **EXAMINER** HM12/0328 Flehr Hohbach Test Albritton & Herbert L FIELDS, I PAPER NUMBER **ART UNIT** Four Embarcadero Center

Fight Hondach Test Albritton & Herbert E Four Embarcadero Center Suite 3400 San Francisco CA 94111-4187

DATE MAILED: 03/28/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)
Offic Action Summary	09/500,376	CHANG ET AL.
	Examiner	Art Unit
•	lesha P Fields	1645
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status		
1) Responsive to communication(s) filed on	·	
2a) This action is FINAL . 2b) ⊠ Th	nis action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.		
Disposition of Claims		
4) Claim(s) is/are pending in the application.		
4a) Of the above claim(s) is/are withdrawn from consideration.		
5) Claim(s) is/are allowed.		
6) Claim(s) is/are rejected.		
7) Claim(s) is/are objected to.		
8) Claims 1-36 are subject to restriction and/or election requirement.		
Application Papers		
9) The specification is objected to by the Examiner.		
10) The drawing(s) filed on is/are objected to by the Examiner.		
11) The proposed drawing correction filed on is: a) □ approved b) □ disapproved.		
12) The oath or declaration is objected to by the Examiner.		
Priority under 35 U.S.C. § 119		
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).		
a)		
1. Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 		
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. & 119(e).		
Attachment(s)		
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	19) Notice of Infor	nmary (PTO-413) Paper No(s) mail Patent Application (PTO-152)

Application/Control Number: 09/500,376

Art Unit: 1645

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-19, drawn to a polypeptide, classified in class 530, subclass 350.
- II. Claims 20-22, drawn to a method of inducing an immunological response, classified in class 424, subclass 191.1.
- III. Claims 23-36, drawn to a method of making a polypeptide, classified in class 435, subclass 69.1.
- 1. Additionally Groups I-III are further restricted according to MPEP 803.04 which recites that nucleotide sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. Applicants are required to elect a single nucleotide sequence or a single protein sequence for examination.
- 2: The inventions are distinct, each from the other because of the following reasons:

 Invention I drawn to a polypeptide and Invention II drawn to a method of inducing
 an immunological are related as product and process of use. The inventions can be
 shown to be distinct if either or both of the following can be shown: (1) the process for
 using the product as claimed can be practiced with another materially different product
 or (2) the product as claimed can be used in a materially different process of using that

Application/Control Number: 09/500,376

Art Unit: 1645

Page 3

product (MPEP § 806.05(h)). In the instant case the polypeptide can be used to

generate antibodies.

Invention III drawn to a method of making a polypeptide is distinct from

Inventions I-II, since it requires additional biological reagents and parameters to make

the polypeptide.

Because these inventions are distinct for the reasons given above and have

acquired a separate status in the art because of their separate classification and their

recognized divergent subject matter, restriction for examination purposes as indicated is

proper.

Applicant is advised that the reply to this requirement to be complete must

include an election of the invention to be examined even though the requirement be

traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to lesha Fields whose telephone number is (703) 306-

3225.

lesha Fields

March 26, 2001

MARK NAVARRO
DRIMARY EXAMINER